share_log

Grail | 10-Q: Quarterly report

Grail | 10-Q: Quarterly report

Grail | 10-Q：季度報表
美股SEC公告 ·  2024/11/13 16:18

Moomoo AI 已提取核心訊息

GRAIL reported Q3 2024 revenue of $28.7 million, up 38% year-over-year, driven by a 57% increase in Galleri test volume despite a 3% decrease in average selling price. Screening revenue grew 52% to $25.4 million while development services revenue declined 18% to $3.3 million. The company posted a net loss of $125.7 million, compared to $891.4 million in Q3 2023.The company implemented a restructuring plan in August 2024 to focus on its core MCED business and reduce costs, resulting in a 25% workforce reduction and $19 million in restructuring charges. Management expects the plan to generate approximately $120 million in annual cost savings and extend cash runway from second half of 2026 into 2028. The company ended the quarter with $853.6 million in cash and cash equivalents.GRAIL continues advancing its PMA submission for Galleri to the FDA while operating as an independent public company following its spin-off from Illumina in June 2024. The company received $932.3 million in disposal funding from Illumina and entered into various agreements to govern the ongoing relationship between the companies, including supply, tax, and stockholder arrangements.
GRAIL reported Q3 2024 revenue of $28.7 million, up 38% year-over-year, driven by a 57% increase in Galleri test volume despite a 3% decrease in average selling price. Screening revenue grew 52% to $25.4 million while development services revenue declined 18% to $3.3 million. The company posted a net loss of $125.7 million, compared to $891.4 million in Q3 2023.The company implemented a restructuring plan in August 2024 to focus on its core MCED business and reduce costs, resulting in a 25% workforce reduction and $19 million in restructuring charges. Management expects the plan to generate approximately $120 million in annual cost savings and extend cash runway from second half of 2026 into 2028. The company ended the quarter with $853.6 million in cash and cash equivalents.GRAIL continues advancing its PMA submission for Galleri to the FDA while operating as an independent public company following its spin-off from Illumina in June 2024. The company received $932.3 million in disposal funding from Illumina and entered into various agreements to govern the ongoing relationship between the companies, including supply, tax, and stockholder arrangements.
GRAIL報告2024財年第三季度營業收入爲2870萬美元，比去年同期增長38%，儘管平均售價下降了3%，但Galleri檢測的成交量仍增長了57%。篩查收入增長52%，達到2540萬美元，而開發服務收入下降18%，降至330萬美元。公司報告淨虧損爲12570萬美元，而2023年第三季度的淨虧損爲89140萬美元。公司在2024年8月實施了一項重組計劃，專注於其核心MCED業務並減少成本，導致25%的員工裁減和1900萬美元的重組費用。管理層預計該計劃將每年產生約12000萬美元的成本節約，並將現金流延續從2026年下半年延長至2028年。公司在本季度末的現金及現金等價物爲85360萬美元。GRAIL繼續推動Galleri的PMA提交給FDA，同時在2024年6月從Illumina獨立後，以獨立上市公司的身份運營。公司從Illumina獲得了93230萬美元的處置資金，並簽訂了多項協議以監管兩家公司之間的持續關係，包括供應、稅務和股東安排。
GRAIL報告2024財年第三季度營業收入爲2870萬美元，比去年同期增長38%，儘管平均售價下降了3%，但Galleri檢測的成交量仍增長了57%。篩查收入增長52%，達到2540萬美元，而開發服務收入下降18%，降至330萬美元。公司報告淨虧損爲12570萬美元，而2023年第三季度的淨虧損爲89140萬美元。公司在2024年8月實施了一項重組計劃，專注於其核心MCED業務並減少成本，導致25%的員工裁減和1900萬美元的重組費用。管理層預計該計劃將每年產生約12000萬美元的成本節約，並將現金流延續從2026年下半年延長至2028年。公司在本季度末的現金及現金等價物爲85360萬美元。GRAIL繼續推動Galleri的PMA提交給FDA，同時在2024年6月從Illumina獨立後，以獨立上市公司的身份運營。公司從Illumina獲得了93230萬美元的處置資金，並簽訂了多項協議以監管兩家公司之間的持續關係，包括供應、稅務和股東安排。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

獨立文件9  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Prenetics Global
    PRE
    -- 4.0000
    NeoGenomics
    NEO
    -- 9.620
    Fulgent Genetics
    FLGT
    -- 17.050
    恩佐生化
    ENZ
    -- 0.431
    Personalis
    PSNL
    -- 3.620
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日